Article
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Cancer discovery - 1 Jul 2017
Juric Dejan, Krop Ian, Ramanathan Ramesh K, Wilson Timothy R, Ware Joseph A, Sanabria Bohorquez Sandra M, Savage Heidi M, Sampath Deepak, Salphati Laurent, Lin Ray S, Jin Huan, Parmar Hema, Hsu Jerry Y, Von Hoff Daniel D, Baselga José
Abstract excerpt
Taselisib is a potent and selective tumor growth inhibitor through PI3K pathway suppression. Thirty-four patients with locally advanced or metastatic solid tumors were treated (phase I study, modified 3+3 dose escalation; 5 cohorts; 3-16 mg taselisib once-daily capsule). Taselisib pharmacokinetics were dose-proportional; mean half-life was 40 hours. Frequent dose-dependent, treatment-related adverse events...
Topics
Join the communities discussing this publication.